Fluocinolone + Hydroquinone + Tretinoin


Thông tin thuốc gốc
Chỉ định và Liều dùng
Topical/Cutaneous
Moderate to severe melasma of the face
Adult: Available preparation:
Each g of cream contains fluocinolone acetonide 0.1 mg, hydroquinone 40 mg, and tretinoin 0.5 mg

Short-term treatment: Apply thinly once daily at night (at least 30 minutes before bedtime) onto the affected area(s) including approx 1/2 inch of normal appearing skin surrounding each lesion. Continue the therapy until control is achieved. Max treatment duration: 8 weeks.
Thận trọng
Patient receiving hormonal contraceptives may consider changing to non-hormonal contraceptive measures. Not intended for the maintenance treatment of melasma. Use in darker skin types (Fitzpatrick skin types V and VI) has not been evaluated. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Cutaneous hypersensitivity/contact dermatitis, exogenous ochronosis, Kaposi’s sarcoma (prolonged use); systemic effects (e.g. adrenal suppression, manifestations of Cushing’s syndrome, hyperglycaemia, glycosuria); visual disturbances (e.g. blurred vision, cataract, glaucoma, central serous chorioretinopathy).
Gastrointestinal disorders: Dry mouth.
General disorders and administration site conditions: Application site reactions (e.g. local irritation, inflammation, erythema, burning sensation, desquamation, dryness, xeroderma, pruritus).
Nervous system disorders: Paraesthesia, hyperaesthesia.
Skin and subcutaneous tissue disorders: Acne, telangiectasia, pigmentary changes, papules, acne-like rash, rosacea, rash, vesicles.
Thông tin tư vấn bệnh nhân
Avoid exposure to sunlight and UV light; use sunscreen or wear protective clothing during the day. Do not use occlusive dressings on the affected area. Avoid contact with mucous membranes, eyes, nose, angles of the mouth, and abraded skin.
Chỉ số theo dõi
May consider confirming the pregnancy status prior to treatment initiation in women of reproductive potential. Monitor for signs or symptoms of hypothalamic-pituitary-adrenal (HPA) axis suppression.
Quá liều
Symptoms: Excessive marked peeling, redness, and discomfort at the application site. Management: Symptomatic treatment. Apply less frequently or discontinue use altogether.
Tương tác
May cause additive photosensitivity when used concomitantly with known photosensitising agents (e.g. glimepiride, chlorpromazine, hydrochlorothiazide).
Tương tác với thức ăn
May enhance adverse effects with vitamin A-containing foods (e.g. cod liver oil, halibut fish oil).
Tác dụng
Description:
Mechanism of Action: Fluocinolone acetonide is a topical corticosteroid. It induces phospholipase A2 inhibitory proteins (lipocortins) and sequential inhibition of arachidonic acid release, thus reducing the formation, release, and activity of endogenous chemical mediators of inflammation (e.g. kinins, liposomal enzymes, histamines, prostaglandins).
Hydroquinone suppresses the metabolic processes of melanocytes, particularly the inhibition of the enzymatic oxidation of tyrosine to 3,4-dihydroxyphenylalanine (DOPA), thereby producing reversible depigmentation of the skin.
Tretinoin, a derivative of vitamin A, modifies epithelial growth and differentiation.
Pharmacokinetics:
Absorption: Minimally absorbed percutaneously.
Metabolism: Metabolised in the liver (for the small amount absorbed).
Excretion: Via urine and faeces.
Đặc tính

Chemical Structure Image
Fluocinolone acetonide

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 6215, Fluocinolone acetonide. https://pubchem.ncbi.nlm.nih.gov/compound/Fluocinolone-acetonide. Accessed Jan. 25, 2021.


Chemical Structure Image
Hydroquinone

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 785, Hydroquinone. https://pubchem.ncbi.nlm.nih.gov/compound/Hydroquinone. Accessed Oct. 24, 2023.


Chemical Structure Image
Tretinoin

Source: National Center for Biotechnology Information. PubChem Database. Tretinoin, CID=444795, https://pubchem.ncbi.nlm.nih.gov/compound/Tretinoin (accessed on Jan. 23, 2020)

Bảo quản
Store between 2-8°C. Do not freeze.
Phân loại MIMS
Các sản phẩm da liễu khác
Tài liệu tham khảo
Anon. Fluocinolone (Topical). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 09/10/2020.

Anon. Fluocinolone, Hydroquinone, and Tretinoin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 09/10/2020.

Anon. Hydroquinone. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 09/10/2020.

Anon. Tretinoin (Topical). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 09/10/2020.

Buckingham R (ed). Hydroquinone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/10/2020.

Fluocinolone; Hydroquinone; Tretinoin. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com/. Accessed 06/11/2020.

Tri-Lucent Cream (HOE Pharmaceuticals Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 09/10/2020.

Tri-Luma Cream (Galderma Laboratories, L.P.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 09/10/2020.

Tri-Luma Cream (Zuellig Pharma Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my/. Accessed 09/10/2020.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Fluocinolone + Hydroquinone + Tretinoin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in